223 related articles for article (PubMed ID: 27510521)
1. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.
Fihlman M; Hemmilä T; Hagelberg NM; Kuusniemi K; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
Eur J Clin Pharmacol; 2016 Nov; 72(11):1363-1371. PubMed ID: 27510521
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole greatly increases the exposure to oral buprenorphine.
Fihlman M; Hemmilä T; Hagelberg NM; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
Eur J Clin Pharmacol; 2018 Dec; 74(12):1615-1622. PubMed ID: 30167757
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
4. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.
Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Vyyryläinen H; Laine K
Antimicrob Agents Chemother; 2006 Jun; 50(6):1967-72. PubMed ID: 16723553
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole and fluconazole increase the exposure to oral diazepam.
Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole drastically increases exposure to oral oxycodone.
Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.
Bai SA; Xiang Q; Finn A
Clin Ther; 2016 Feb; 38(2):358-69. PubMed ID: 26804639
[TBL] [Abstract][Full Text] [Related]
9. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl.
Saari TI; Laine K; Neuvonen M; Neuvonen PJ; Olkkola KT
Eur J Clin Pharmacol; 2008 Jan; 64(1):25-30. PubMed ID: 17987285
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT
Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765
[TBL] [Abstract][Full Text] [Related]
11. Effect of voriconazole on the pharmacokinetics of diclofenac.
Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Laine K
Fundam Clin Pharmacol; 2007 Dec; 21(6):651-6. PubMed ID: 18034666
[TBL] [Abstract][Full Text] [Related]
12. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Br J Clin Pharmacol; 2007 Jan; 63(1):116-20. PubMed ID: 16822278
[TBL] [Abstract][Full Text] [Related]
13. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
Kuhlman JJ; Lalani S; Magluilo J; Levine B; Darwin WD
J Anal Toxicol; 1996 Oct; 20(6):369-78. PubMed ID: 8889672
[TBL] [Abstract][Full Text] [Related]
14. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
[TBL] [Abstract][Full Text] [Related]
15. A randomized, phase I, 3-way crossover study to examine the effects of food on the pharmacokinetics of single doses of 400 mg posaconazole oral suspension in healthy male Taiwanese subjects.
Lin TY; Yang MH; Chang FY
Ther Drug Monit; 2013 Apr; 35(2):223-7. PubMed ID: 23503449
[TBL] [Abstract][Full Text] [Related]
16. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Apr; 79(4):362-70. PubMed ID: 16580904
[TBL] [Abstract][Full Text] [Related]
17. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
Purkins L; Wood N; Kleinermans D; Love ER
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):62-8. PubMed ID: 14616416
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.
Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT
J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859
[TBL] [Abstract][Full Text] [Related]
19. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.
van Hoogdalem MW; Johnson TN; McPhail BT; Kamatkar S; Wexelblatt SL; Ward LP; Christians U; Akinbi HT; Vinks AA; Mizuno T
Clin Pharmacol Ther; 2022 Feb; 111(2):496-508. PubMed ID: 34679189
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Single Doses of Methadone and Buprenorphine in Blood and Oral Fluid in Healthy Volunteers and Correlation With Effects on Psychomotor and Cognitive Functions.
Strand MC; Ramaekers JG; Gjerde H; Mørland J; Vindenes V
J Clin Psychopharmacol; 2019; 39(5):489-493. PubMed ID: 31305338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]